Prostate Cancer | Specialty

Combo Trials Aim to Clarify Optimal Radium-223 Use in mCRPC

August 16th 2016

Russell Szmulewitz, MD, discusses the unknown optimal use of radium-223 dichloride (Xofigo), the appropriate time to administer it, and the associated challenges with the agent for the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC

August 11th 2016

Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Immunotherapy Advances Again Propel Progress in GU Malignancies

August 11th 2016

Randy F. Sweis, MD, covers the immunotherapy advancements in prostate cancer, renal cell carcinoma, and bladder cancer, and what refinement lies ahead in each of these areas.

Dr. Neal Shore on Increasing Healthcare Costs and Metastasis Risk in Prostate Cancer

August 7th 2016

​Neal Shore, MD, medical director of the Carolina Urologic Research Institute, discusses a retrospective study investigating the relationship between treatment costs and the timing of diagnosis of metastases in prostate cancer.

Caring for US Veterans Helped Lead Iraqi Immigrant to Develop Prostate Cancer Advances

August 6th 2016

Maha H. Hussain, MB ChB, whose work has helped advance treatment and care of men with prostate cancer, was honored in the Genitourinary Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to recognize leaders in the field.

Dr. Luke Nordquist on Radium-223 Retreatment

August 4th 2016

Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a multicenter, prospective study of radium-223 retreatment in metastatic castration-resistant prostate cancer (mCRPC).

Expert Defends Merits of Prostatectomy

August 2nd 2016

Gregory Zagaja, MD, discusses the benefits of radical prostatectomy and other ongoing developments with surgery in prostate cancer.

Expert Projects Next Steps in Advanced Prostate Cancer

August 2nd 2016

Russell Szmulewitz, MD, discusses optimal treatment strategies for patients with metastatic castration-resistant prostate cancer and highlights emerging therapies in the therapeutic landscape.

Gyorgy Petrovics on Frequency of BRCA Mutations in African American Prostate Cancer Patients

August 2nd 2016

Gyorgy Petrovics, PhD, associate director, Center for Prostate Disease Research (CPDR), research associate professor in the department of surgery at the Uniformed Services University of the Health Sciences (USUHS), discusses BRCA1 and BRCA2 mutations in African American prostate cancer patients.

Expert Discusses Outcomes With Radiation Therapy in Locally Advanced Prostate Cancer

July 30th 2016

Stanley Liauw, MD, discusses the evolving role of radiation therapy in locally advanced prostate cancer and how it compares with surgical options.

Galeterone Prostate Cancer Trial Closes as PFS Rates Miss Mark

July 26th 2016

The pivotal phase III trial ARMOR 3-SV will be discontinued based on recommendations made by the trial's independent data monitoring committee.

Optimal Radium-223 Use Explored as Evolution of mCRPC Care Continues

July 26th 2016

Daniel P. Petrylak, MD, professor of Medicine, Yale Cancer Center, discusses his vision for radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and how it integrates with chemotherapy and other agents for treatment of this patient population.

Dreicer Addresses Key Questions With Radium-223 in mCRPC

July 25th 2016

Robert Dreicer, MD, discusses the key questions that surround the optimal use and sequencing of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and how the treatment has altered the field of radiopharmaceuticals.

Dr. Oh on Recognizing Symptom Burden in Advanced Prostate Cancer

July 22nd 2016

William K. Oh, MD, professor of Medicine, Hematology, and Medical Oncology, and Urology, Mount Sinai Hospital, discusses a global study aimed at recognizing symptom burden in patients with advanced prostate cancer.

Expert Stresses Importance of PSA-Based Screening in Early-Stage Prostate Cancer

July 21st 2016

Scott Eggener, MD, discusses the implications of the Prostate, Lung, Colorectal, and Ovary trial update, and shares his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer.

CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC

July 19th 2016

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.

Patnaik Highlights Evolution Toward Immunotherapy in Prostate Cancer

July 18th 2016

Akash Patnaik, MD, discusses immunotherapy and personalized medicine tactics in the field of prostate cancer, as well as the work that needs to be done with existing targeted therapies and biomarker development.

Dr. Charles Ryan on Impact of IMAAGEN Trial in Nonmetastatic CRPC

July 15th 2016

Dr. Crawford on Ongoing Research With Radium-223 in mCRPC

July 15th 2016

E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses ongoing research with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Stadler Shares Treatment Updates, Questions in Castration-Sensitive Prostate Cancer

July 12th 2016

Walter M. Stadler, MD, discusses emerging therapies, the most overriding challenges in a specific subset of patients, and understanding the evolving role of chemotherapy in metastatic castration-sensitive prostate cancer.